The New South Wales government has announced a commitment of $5 million in funding for silicosis research and a patient support program — this initiative aims to assist individuals and their families dealing with the health risks associated with exposure to silica dust.
Minister for Medical Research David Harris stated: “With this funding, we will put NSW at the forefront of research in this vital area – working with industry partners to better understand the occurrence of silicosis in the community.
“We owe it to our community to do everything we can to find better treatments and improve the health outcomes of those living with a silicosis diagnosis.”
Following the groundbreaking ban on manufactured stone, the NSW government is supporting research focused on the diagnosis, treatment, and care of diseases related to silica dust.
Administered by icare and the Dust Diseases Board, the grant will provide $5 million over three years to the Asbestos and Dust Diseases Research Institute (ADDRI).
This funding will drive research into the prevention, diagnosis, therapeutic procedures, and treatment of silica dust-related diseases, ultimately improving outcomes for individuals diagnosed with silicosis.
ADDRI’s current focus includes accelerating laboratory-based research into early diagnosis and treatments for silicosis, reducing barriers to diagnosis through the establishment of a specialist Dust Disease Multi-Disciplinary Team — improving general practitioner education about dust diseases, and expanding tissue sample collection through the institute’s Biobank.
Renowned internationally for its leadership, ADDRI aims to save lives through laboratory research, clinical sciences, and prevention and public health initiatives.
NSW Minister for Work Health and Safety Sophie Cotsis stated: “[This] funding announcement delivers on our election promise to invest in research and care programs for NSW workers living with silicosis.”
ADDRI CEO Kim Brislane said: “This funding allows us to build on our program of research into prevention, diagnosis, therapeutic procedures, and treatments of silicosis in Australia.”
icare Group Executive for Lifetime Care Dr Nick Allsop emphasised the importance of research in developing better care for workers with silicosis and improving treatment outcomes. He stated: “Research is our best chance to uncover ways to prevent silicosis and stop its progression.”
